{
  "retracted": false,
  "timestamp": 1501545600000,
  "updates": [
    {
      "timestamp": 1496238049614,
      "identifier": {
        "doi": "10.1016/j.leukres.2017.02.007"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1016/j.leukres.2016.09.012"
  },
  "journal": "Leukemia Research",
  "publisher": "Elsevier BV",
  "title": "Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]"
}
